In PepBank now:147 peptides, 6 blends and 13 other compounds97,577 study results from 17,383 studies8,473 clinical trialsUpdated
Comparing 2 records · Data version 308560
Swipe sideways to see every peptide.
| Peptide | Natural peptide Oxytocin | ||
|---|---|---|---|
| Identity | |||
| Kind | Small molecule | Natural peptide | |
| Area | Sexual health and hormones | Sexual health and hormones | |
| Evidence | |||
| Amount of evidence | 153 | 3,492 (plus 1,148 on natural levels, listed separately) | |
| Evidence level | Has results from studies in people | Has results from studies in people | |
| Safety | |||
| Safety results | 18 (5 in people) | 157 (152 in people) | |
| Status | |||
| Approval | |||
| Sport (WADA) | |||
| Registered trials | 25 | 690 · 65 active238 more mention it but do not test it | |
Shared outcomes
From the regulatory data of each peptide.
Its most advanced trial is in phase 3. The FDA, the EMA and the other sources we use show no approval (as of 21 Oct 2026).
Outcome groups with study results for at least two of these peptides. Counts include only results from studies that gave the peptide. Bar length is the number of results, on one scale. The bars show how much was studied, not how large an effect was. A peptide with more studies can look stronger here without being stronger. For results, see the randomized results above.
| Outcome group | Enclomiphene | Oxytocin |
|---|---|---|
| Adverse eventsWhole body | 55 | 1261233 |
| Receptor activity and mechanismWhole body |
PepBank is a research reference. Talk to a doctor before you use any peptide.
The FDA label for Pitocin says: “Antepartum: medically indicated induction of labor, stimulation or reinforcement of labor, adjunctive therapy in incomplete or inevitable abortion” No central EU authorisation (EMA).
351916
28960801472 |
| Sex hormones and fertilityReproductive and sexual health | 89324017 | 150328632 |
|---|
| PharmacokineticsPharmacology | 66 | 9168203 |
|---|
| Stress hormonesEndocrine and hormones | 22 | 7560123 |
|---|
| Kidney functionKidney and urinary | 11 | 42735 |
|---|
| Bone and jointMusculoskeletal | 211 | 2020 |
|---|
| Tumor growthCancer | 725 | 6411 |
|---|
| LipidsMetabolic and weight | 11 | 541 |
|---|
| Growth hormone and IGF-1Endocrine and hormones | 211 | 22 |
|---|
| Thyroid functionEndocrine and hormones | 11 | 11 |
|---|
For each outcome that two or more peptides have results for: the best result of a single randomized trial, on the same measure (the same kind of number, the same unit). When a trial has several dose arms, the cell shows the highest dose arm. The trials differ in people, length and dose, so a gap between two cells is not proof that one peptide works better.
No outcome has a randomized-trial result on the same measure for two or more of these peptides yet.
The other peptides have no randomized result on the same measure, so these results cannot be set side by side.
| Outcome | Enclomiphene | Oxytocin |
|---|---|---|
| Sex hormones and fertilityEndocrine and hormonesCompared as: value in the arm that got the peptide, in % | No comparable result 22 randomized-trial results measure it in another way or another unit. | 14.4% Mean percent change testosterone Dose studied: 24 IUn = 452020 |
| LipidsCardiovascularCompared as: difference from placebo, in mg/dl | No comparable result 1 randomized-trial result measure it in another way or another unit. | −19.3 mg/dL LDL cholesterol change Dose studied: 24 IU 4 times per day8 weeksn = 212021 |
| Growth hormone and IGF-1Endocrine and hormonesCompared as: value in the arm that got the peptide, in mu/l | No comparable result 1 randomized-trial result measure it in another way or another unit. | 96 mU/l Peak plasma GH Saline: 106 mU/l n = 61988 |
| Stress hormonesEndocrine and hormonesCompared as: value in the arm that got the peptide, in ng/l | No comparable result 2 randomized-trial results measure it in another way or another unit. | 266 ng/l Peak plasma ACTH Saline: 281 ng/l n = 61988 |
| PharmacokineticsPharmacologyCompared as: value in the arm that got the peptide, in effect size | No randomized trial result 6 results from other study designs. | −1.12 effect size Effect size Dose studied: 48 IU/day6 weeksn = 1032020 |
| Receptor activity and mechanismPharmacologyCompared as: value in the arm that got the peptide, in proteins | No randomized trial result 35 results from other study designs. | 198 proteins Differentially expressed proteins Dose studied: 24 IUsingle dosen = 192026 |
No comparable result
22 randomized-trial results measure it in another way or another unit.
14.4%
Mean percent change testosterone
Dose studied: 24 IUn = 452020
No comparable result
1 randomized-trial result measure it in another way or another unit.
−19.3 mg/dL
LDL cholesterol change
Dose studied: 24 IU 4 times per day8 weeksn = 212021
No comparable result
1 randomized-trial result measure it in another way or another unit.
96 mU/l
Peak plasma GH
Saline: 106 mU/l
n = 61988
No comparable result
2 randomized-trial results measure it in another way or another unit.
266 ng/l
Peak plasma ACTH
Saline: 281 ng/l
n = 61988
No randomized trial result
6 results from other study designs.
−1.12 effect size
Effect size
Dose studied: 48 IU/day6 weeksn = 1032020
No randomized trial result
35 results from other study designs.
198 proteins
Differentially expressed proteins
Dose studied: 24 IUsingle dosen = 192026
Registered trials, ranked by phase (late phases first), then posted results and enrollment. Status is the registry status. Study results come from published studies. Results posted at ClinicalTrials.gov are shown on each trial page.
Top 3 of 25 trials, ranked by phase, then posted results and enrollment: 3 completed · 3 with posted results · source ClinicalTrials.gov (opens in a new tab)
Repros Therapeutics Inc.499 participantsMay 2012 to Oct 2013
Secondary Hypogonadism
Repros Therapeutics Inc.181 participantsNov 2012 to Sept 2013
Secondary Hypogonadism
Repros Therapeutics Inc.151 participantsAug 2012 to Mar 2013
Secondary Hypogonadism
Top 3 of 690 trials, ranked by phase, then posted results and enrollment: 3 completed · 3 with posted results · source ClinicalTrials.gov (opens in a new tab)
University of Alabama at Birmingham1,798 participantsNov 2008 to Jun 2010
Uterine Atony · Postpartum Hemorrhage
Northwestern University1,003 participants28 Sept 2015 to 28 Sept 2020
Dystocia
University of Zimbabwe506 participants8 Apr 2018 to 30 Jun 2019
Post Partum Hemorrhage
238 more mention it but do not test it. They only measure it or name it in their text.